1. ALLA AKTIER
  2. NYHETER
  3. AROCELL

AroCell

Nyheter AroCell Nyheter alla bolag

New patent approved on the US market

AroCell announces today that the US Patent Office has approved and issued AroCell's patent US 11,959,919 B2, entitled "Predicting cancer progression".

The patent is one of AroCell's early patents that demonstrated the clinical significance of serum TK1 protein measurements using the specific antibodies against the C-terminal region of TK1 in cancer. This patent extends a previously approved European patent with the number EP 1,627,230 B1. The new patent is now valid until 2034.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

New patent approved on the US market

Datum 2024-04-18, kl 11:35
Källa MFN
Bifogade filer
New patent approved on the US market
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.